Absorption Systems, a global leader in developing GLP and GMP-compliant in vitro cell-based as well as in vivo animal models for clients in the pharmaceutical and gene/cell therapy space, announces the acquisition of TGA Sciences, Inc., a contract R&D laboratory located in Medford, MA, just outside the pharma/biotech hub of Cambridge. TGA Sciences, Inc. will become TGA Bioservices LLC, a subsidiary of Absorption Systems.
The acquisition achieves two important goals for Absorption Systems' growth strategy. The first is expanding Absorption Systems' expertise in research and GxP assay development services. The second strategic goal is to position Absorption Systems closer to customers in the expanding Boston/Cambridge biotech hub.
Michael Settles, who founded TGA Sciences, Inc., will continue to lead TGA BioServices as VP of Corporate Development . TGA Sciences, Inc. has emerged as a leader in the development, validation, and performance of R&D as well as regulated GLP/cGMP assays to support the development and approval of a broad range of small molecule and biological therapeutics. TGA BioServices has over 15,000 square feet of laboratory space, with analytical, R&D, bioassay, and immunochemistry labs as well as an animal facility that is AAALAC-accredited, USDA-registered, and OLAW-certified.
Patrick Dentinger, President and CEO of Absorption Systems, commented that "This deal is a natural fit for both companies, as our areas of combined expertise offer a more comprehensive service package to our expanding client base. The newly created subsidiary TGA BioServices is strategically positioned in Boston to respond to both the emerging cell and gene therapy service market and the ever-expanding small molecule market."
Michael Settles, President and CEO of TGA Sciences, Inc. said that "After more than 20 years of providing services to our mostly local clientele, I am excited to join the Absorption Systems family because of their reputation for delivering quality services. This combination of the two companies allows us to improve our infrastructure and overall services to our already long list of clients and we look forward to moving forward."
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. From early stage research through commercial and post market surveillance, Absorption Systems is committed to providing the most physiologically relevant test systems with highest quality. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.
About ACF Bioservices
ACF Bioservices (an Absorption Systems company) has the expertise and relevant experience needed to provide analytical support for gene and cell therapy products through every stage of development. Potency assays are on the critical path, and ACF offers de novo development, optimization, qualification, validation, and cGMP-compliant final product and product release testing services for both allogenic and autologous therapies. We have the capability to develop both in vitro and in vivo models to predict human outcomes and establish correlations between animal studies and in vitro cell-based assays. Our fully compliant facilities and studies have been inspected by the FDA, USDA, and AAALAC. ACF has over 20 years of business operating expertise developing proprietary assays, combining our skills in cell and molecular biology, assay development and validation, bioanalytical and immunochemical quantitation, statistical analysis, and regulatory affairs in a single-source collaboration. Please contact ACF Bioservices for additional information at acfbioservices.com.